NRSNW — NeuroSense Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875091 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,028,000 | 166,000 | 2,588,000 |
| Jun 2025 | — | — | — | — | 1,684,000 | 666,000 | 2,203,000 |
| Dec 2024 | 0 | — | -1,771,000 | -1,801,000 | 4,575,000 | 3,378,000 | 1,992,000 |
| Sep 2024 | 0 | — | -2,107,000 | -2,148,000 | 984,000 | 344,000 | 3,802,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-47,785,000
Inventory
—
Receivables
$33,000
ST Investments
—
EBIT TTM
$-3,878,000
Pretax Income TTM
$-3,949,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,085,000 | -11,125,000 | 1,028,000 | 2,588,000 | — | -7,671,000 |
| Dec 2024 | 0 | -9,902,000 | -10,210,000 | 4,575,000 | 1,992,000 | — | -10,135,000 |
| Dec 2023 | 0 | -12,049,000 | -10,107,000 | 3,185,000 | 4,944,000 | — | -8,354,000 |
| Dec 2022 | 0 | -10,554,000 | -10,492,000 | 7,710,000 | 2,091,000 | — | -7,616,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroSense Announces Pricing of Insider-Led PIPE Financing
2026-04-28 18:30 · Yahoo
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
2026-04-06 13:20 · Yahoo
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
2026-04-03 14:02 · Yahoo
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2026-03-31 13:20 · Yahoo
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
2026-03-24 13:00 · Yahoo
/C O R R E C T I O N -- NeuroSense/
2026-03-18 14:44 · Yahoo
NeuroSense to Host Investor Webinar on December 8, 2025
2025-11-03 14:15 · Yahoo
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
2025-10-06 13:00 · Yahoo
Sector Update: Health Care Stocks Retreat Late Afternoon
2025-09-10 19:52 · Yahoo
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
2025-09-10 18:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.